BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21922203)

  • 1. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
    Atherton PJ; Burger KN; Loprinzi CL; Neben Wittich MA; Miller RC; Jatoi A; Sloan JA
    Support Care Cancer; 2012 Aug; 20(8):1729-35. PubMed ID: 21922203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).
    Neben-Wittich MA; Atherton PJ; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Loprinzi CL; Burger KN; Martenson JA; Miller RC
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):397-402. PubMed ID: 20888137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
    Miller RC; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Stoffel TJ; Haselow RE; Schaefer PL; Bearden JD; Atherton PJ; Loprinzi CL; Martenson JA
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1460-6. PubMed ID: 20800381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-Blind, Placebo-Controlled Pilot Study of Processed Ultra Emu Oil Versus Placebo in the Prevention of Radiation Dermatitis.
    Rollmann DC; Novotny PJ; Petersen IA; Garces YI; Bauer HJ; Yan ES; Wahner-Roedler D; Vincent A; Sloan JA; Issa Laack NN
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):650-8. PubMed ID: 25936812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?
    Chan A; Tan EH
    Support Care Cancer; 2011 Oct; 19(10):1667-74. PubMed ID: 20820812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).
    Sio TT; Atherton PJ; Birckhead BJ; Schwartz DJ; Sloan JA; Seisler DK; Martenson JA; Loprinzi CL; Griffin PC; Morton RF; Anders JC; Stoffel TJ; Haselow RE; Mowat RB; Wittich MA; Bearden JD; Miller RC
    Support Care Cancer; 2016 Sep; 24(9):3847-55. PubMed ID: 27075674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).
    Jatoi A; Dakhil SR; Sloan JA; Kugler JW; Rowland KM; Schaefer PL; Novotny PJ; Wender DB; Gross HM; Loprinzi CL;
    Support Care Cancer; 2011 Oct; 19(10):1601-7. PubMed ID: 20820817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    PĂ©rez-Soler R
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
    Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
    Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
    Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
    Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.
    Ho AY; Olm-Shipman M; Zhang Z; Siu CT; Wilgucki M; Phung A; Arnold BB; Porinchak M; Lacouture M; McCormick B; Powell SN; Gelblum DY
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):325-333. PubMed ID: 29726361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
    Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
    BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.